USAID's Reaching Impact Saturation and Epidemic Control (RISE) program assists countries to respond to the HIV and COVID-19 pandemics, providing technical assistance, service delivery, research, and crosscutting health system support to address critical HIV and COVID-19 pandemic response priorities. All data shared are cumulative, unless otherwise noted.

RISE programming has addressed challenges in 22 countries:

- HIV response supported in 14 countries
- COVID-19 response supported in 15 countries
- COVID-19 Test-to-Treat programming in 5 countries
- HIV technical assistance provided in 8 countries
- Hosting HIV and/or HPV prevention research studies 2 countries

147,307

people provided with lifesaving ART across 3 countries (Burundi, Cote d'Ivoire, and Nigeria)

74,166

people diagnosed with HIV through RISE testing services

98.9% of clients testing positive linked to antiretroviral therapy services

96.0%

of clients on ART are virally suppressed (FY22)

4,369

facilities supported with COVID-19 case management technical assistance

17,644,096 COVID-19 vaccines administered

14 RISE-supported PSA plants

for medical oxygen generation

35,462

RISE clients currently using PrEP

98,077

clients provided with Voluntary Medical Male Circumcision for HIV prevention

22,336

health workers trained on COVID-19 case management

63,630

health workers trained on COVID-19 related IPC and/or WASH

29

national policies, protocols, or guidelines developed or adapted with USG and RISE support